Cargando...
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML
Bcr-abl kinase inhibitors have provided proof of principal that targeted therapy holds great promise for the treatment of cancer. However, despite the success of these agents in treating chronic myelogenous leukemia (CML), the majority of patients continue to present with minimal residual disease co...
Gardado en:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2010
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3285111/ https://ncbi.nlm.nih.gov/pubmed/20382130 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2010.04.003 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|